Reversing Parkinson’s, diabetes, blindness. Meet Ali Afshar, CEO of Mytos

What if the biggest barrier to life-changing medicine wasn’t science, but the cost of making it?Harriet speaks with Ali Afshar, the co-founder and CEO of Mytos, a biotech company automating the manufacturing of human tissue to make regenerative medicine affordable and accessible at scale.Ali believes that within 50 years, every tissue in the body will be replaceable, and that the way there is through engineering, rather than traditional drug discovery.They get into:Why tissue replacement works where drugs fail, and what a 90% fail rate says about the pharmaceutical industryThe conditions Mytos is targeting first, from Parkinson’s and diabetes to macular degenerationWhy the UK was the right place to launch, and the role sovereign nations play in funding biotech infrastructureTech as a deflationary force, and Ali’s first principles belief that better healthcare should cost lessAnd why keeping hardware, software and biology in one vertically integrated team is non-negotiable.Subscribe for more conversations with founders, builders, and operators shaping the future of technology, capital, and global systems.Check out Mytos:https://www.mytos.bio/ https://www.linkedin.com/company/mytosbio/ https://www.linkedin.com/in/ali-afshar-0246002b/ More on Basis:https://www.buildbasis.com/ https://www.youtube.com/@BasisCapital https://www.linkedin.com/company/basiscapitalltd/ https://www.linkedin.com/in/harrietsgreen